Call 1-800-615-3055 anytime to discuss your treatment options.

Clinical Trials by Cancer Type

Learn More About This Topic: Chat with Us | Email Us

All Cancer Types

A Phase I Study of High-Dose IV Vitamin C Treatment in Patients with Solid Tumors

Breast

A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer

A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI- 272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer

A Phase 3, Randomized, Open Label, Two-Arm Study of Neratinib plus Paclitaxel versus Trastuzumab plus Paclitaxel as First-Line Treatment for ErbB-2, Positive Locally Recurrent or Metastatic Breast Cancer

TDM4370g/BO21977: A Randomized, Multicenter, Phase III, Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

A Phase II, Open Label, Non-Randomized, Multi-Center, Pilot, Efficacy Study of [F-18] RGD-K5 Positron Emission Tomography (PET) as a Tool ot Monitor Response to an Anti-angiogenic Drug

A Phase 3 Randomized Open Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer

A Randomized Double—blind Placebo-Controlled Trial of Neratinib (HKI- 272) After Trastuzumab in Women with Early-Stage HER2-/neu Overexpressed/Amplified Breast Cancer

A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination with Exemestane vs. Exemestane Alone as Second Line Therapy in Postmenopausal Women with Locally Advanced or Metastatic ER+/PgR+/ErbB2- Breast Cancer

Genentech VIRGO Registry (AVF4349n): An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer; Archival Tissue Collection Sub-Study in Assocatioin with Study AVF4349n; DNA Repository Sub-Study in Association with Study AVF4349n

Colon

A Phase II, Open Label, Non-Randomized, Multi-Center, Pilot, Efficacy Study of [F-18] RGD-K5 Positron Emission Tomography (PET) as a Tool ot Monitor Response to an Anti-angiogenic Drug

Esophageal

A Phase II/III Open label, Non-Randomized, Multi-Center Study of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

Laryngeal

A Phase II/III Open label, Non-Randomized, Multi-Center Study of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

Liver

Use of TheraSphere® Microspheres Alone or in Combination w/ Concomitant IV Chemotherapy, or Hepatic Artery Chemotherapy or Hepatic Artery Chemoembolization for the Treatment of Unresectable Primary or Metastatic Tumors Involving the Liver

Phase I/II, Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumor

Lung

A Randomized Double-Blind Phase II Study of Carboplatin/Paclitaxel/CT- 322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology

A Phase II, Open Label, Non-Randomized, Multi-Center, Pilot, Efficacy Study of [F-18] RGD-K5 Positron Emission Tomography (PET) as a Tool ot Monitor Response to an Anti-angiogenic Drug

A Phase II/III Open label, Non-Randomized, Multi-Center Study of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

START - Stimulating Targeted Antigenic Responses To NSCLC A multicentre, randomised, double-blind, placebo-controlled, phase III study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in patients with non-small cell lung cancer (NSCLC) with non- resectable stage III disease

Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy

Multiple Myeloma

Sequential Cytoreduction and Allogeneic Cell Therapy for Patients with Multiple Myeloma and Lymphoma

Oral

A Phase II/III Open label, Non-Randomized, Multi-Center Study of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

Ovarian

O-VAX: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse

A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil(R)/Caelyx(R)In Combination Versus PLD Alone in Subjects with Platinum-Resistant Ovarian Cancer.

Phase I/II Study to Evaluate the Safety and Efficacy of an Ovarian Cancer Vaccine Therapy

Pancreatic

APRiCOT-P: Apricoxib in Combination Oncology Treatment – Pancreas - A Randomized, Placebo-controlled, Multicenter, Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with Gemcitabine and Erlotinib in the Treatment of Patients with Advanced Pancreatic Cancer

Pharyngeal

A Phase II/III Open label, Non-Randomized, Multi-Center Study of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

Prostate

A multicenter, randomized, double-blind, phase 3 study of sunitinib plus prednisone versus prednisone in patients with progressive metastatic hormone-refractory prostate cancer after failure of a docetaxel-based chemotherapy regimen

A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration- Resistant Prostate Cancer

Rectal

A Phase II, Open Label, Non-Randomized, Multi-Center, Pilot, Efficacy Study of [F-18] RGD-K5 Positron Emission Tomography (PET) as a Tool ot Monitor Response to an Anti-angiogenic Drug

Chat Now.We're here 24/7.

Watch Cancer Videos